Press release
Oramed to Present at World Diabetes Congress
NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific Officer of Oramed, will deliver two presentations at the World Diabetes Congress, being held July 15-17, 2019 in Rome, Italy. \n\n \nWorld Diabetes Congress Presentation Details:\nPresentation: The End of Injections? Oral Insulin as a ModelDate: Monday, July 15th Time: 2:00 p.m. CEST / 8:00 a.m. EDTLocation: Holiday Inn Rome Aurelia, Italy Presentation: Oral Insulin and Exenatide: Further Steps Toward RealityDate: Tuesday, July 16th Time: 12:00 p.m. CEST / 6:00 a.m. EDTLocation: Holiday Inn Rome Aurelia, ItalyAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD™) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).\nFor more information, the content of which is not part of this press release, please visit www.oramed.com\nForward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceuti...